Cargando…

Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response

Neoadjuvant (preoperative) chemoradiotherapy (CRT) decreases the risk of rectal cancer recurrence and reduces tumour volume prior to surgery. However, response to CRT varies considerably between individuals and factors associated with response are poorly understood. Foxp3(+) regulatory T cells (Treg...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCoy, Melanie J., Hemmings, Chris, Anyaegbu, Chidozie C., Austin, Stephanie J., Lee-Pullen, Tracey F., Miller, Timothy J., Bulsara, Max K., Zeps, Nikolajs, Nowak, Anna K., Lake, Richard A., Platell, Cameron F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386723/ https://www.ncbi.nlm.nih.gov/pubmed/28177891 http://dx.doi.org/10.18632/oncotarget.15048

Ejemplares similares

Low stromal Foxp3(+) regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer
por: McCoy, M J, et al.
Publicado: (2015)

The Prognostic and Predictive Value of SOX2(+) Cell Densities in Patients Treated for Colorectal Cancer
por: Miller, Tim J., et al.
Publicado: (2020)

PD‐L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer
por: Miller, Timothy J., et al.
Publicado: (2021)

Chasing the immortal strand: evidence for nature's way of protecting the breast genome
por: Zeps, Nikolajs, et al.
Publicado: (2011)

Expression of PD-L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion
por: Miller, Tim J., et al.
Publicado: (2018)

Restaging rectal cancer following neoadjuvant chemoradiotherapy
por: Cuicchi, Dajana, et al.
Publicado: (2023)

SPARC, FOXP3, CD8 and CD45 Correlation with Disease Recurrence and Long-Term Disease-Free Survival in Colorectal Cancer
por: Chew, Angela, et al.
Publicado: (2011)

Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density
por: Xu, Yao, et al.
Publicado: (2021)

A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Li, Yi, et al.
Publicado: (2016)

Recent advances in neoadjuvant chemoradiotherapy in locally advanced rectal cancer
por: Kawai, Kazushige, et al.
Publicado: (2018)

Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
por: Sakr, Amr, et al.
Publicado: (2020)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

Tumor-Infiltrating Cytotoxic T Cells and Tumor-Associated Macrophages Correlate With the Outcomes of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Yang, Yuqin, et al.
Publicado: (2021)

Factors influencing downstaging after neoadjuvant long-course chemoradiotherapy in rectal carcinoma
por: Kohl, Valerie K. B., et al.
Publicado: (2022)

Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer()()
por: Smithson, Mary, et al.
Publicado: (2022)

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study
por: Molinari, Chiara, et al.
Publicado: (2011)

Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients
por: Tokuhara, Katsuji, et al.
Publicado: (2016)

Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer
por: Mihmanlı, Mehmet, et al.
Publicado: (2016)

Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives
por: Yamashita, Kimihiro, et al.
Publicado: (2018)

Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients
por: Mei, Shi-Wen, et al.
Publicado: (2020)

Automated Prediction of the Response to Neoadjuvant Chemoradiotherapy in Patients Affected by Rectal Cancer
por: Filitto, Giuseppe, et al.
Publicado: (2022)

Usefulness of close surveillance for rectal cancer patients after neoadjuvant chemoradiotherapy
por: Hsu, Yu-Jen, et al.
Publicado: (2022)

Predictive value of proteomic markers for advanced rectal cancer with neoadjuvant chemoradiotherapy
por: Wang, Hanyang, et al.
Publicado: (2022)

Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer
por: Lee, Hong Seok, et al.
Publicado: (2016)

Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer
por: Klautke, G, et al.
Publicado: (2005)

Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
por: Goedegebuure, R.S.A., et al.
Publicado: (2021)

Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
por: Toomey, Sinead, et al.
Publicado: (2020)

Construction of the Prediction Model for Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy Based on Pretreatment Tumor-Infiltrating Macrophage-Associated Biomarkers
por: Liu, Xing, et al.
Publicado: (2021)

Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma
por: Aryan, Mahmoud, et al.
Publicado: (2021)

PET/CT with Fluorodeoxyglucose During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
por: Travaini, Laura L, et al.
Publicado: (2016)

MRI texture analysis in predicting treatment response to neoadjuvant chemoradiotherapy in rectal cancer
por: Meng, Yankai, et al.
Publicado: (2017)

Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
por: Yoo, Ri Na, et al.
Publicado: (2019)

Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer
por: Chen, Jia-Nan, et al.
Publicado: (2020)

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy
por: Guo, Su-ping, et al.
Publicado: (2021)

Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer
por: Zhang, Qi, et al.
Publicado: (2021)

Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models
por: Li, Moying, et al.
Publicado: (2022)

Clinical prediction model of pathological response following neoadjuvant chemoradiotherapy for rectal cancer
por: Shin, Jung Kyong, et al.
Publicado: (2022)

Comparing neoadjuvant long-course chemoradiotherapy with short-course radiotherapy in rectal cancer
por: Wang, Jian, et al.
Publicado: (2021)

Associations between clinical characteristics and tumor response to neoadjuvant chemoradiotherapy in rectal cancer
por: Pang, Xiaolin, et al.
Publicado: (2021)

An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma
por: Qian, Liwen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e17024sh8t8lob7kkhl9ubbkno